People · Operator

Francis Sarena

Named in public records as an officer, director or promoter · active 2023–2023 · Biotechnology

1
Companies
1
Filings
$66.4M
Combined raised · real
Single
Operator type
Companies
CompanyRoleSectorStageRaised · realValue · estTied
Apexigen, Inc.BiotechnologySeries C$66.4M$85.6M2023
Operator network

Francis Sarena at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.

Scott Smith · 16 companies · 1 sharedScott SmithGordon Ringold · 7 companies · 1 sharedGordon RingoldGeorge Lee · 6 companies · 1 sharedGeorge LeeKAREN LIU · 4 companies · 1 sharedKAREN LIUKenneth Fong · 3 companies · 1 sharedKenneth FongWilliam Rutter · 3 companies · 1 sharedWilliam RutterAmy Wong · 2 companies · 1 sharedAmy WongDan Zabrowski · 2 companies · 1 sharedDan ZabrowskiFrank Hsu · 1 companies · 1 sharedFrank HsuHerb Cross · 1 companies · 1 sharedHerb CrossJakob Dupont · 1 companies · 1 sharedJakob DupontMeenu Karson · 1 companies · 1 sharedMeenu KarsonOvid Trifan · 1 companies · 1 sharedOvid TrifanSamuel Wertheimer · 1 companies · 1 sharedSamuel WertheimerWilliam Duke, Jr. · 1 companies · 1 sharedWilliam Duke, Jr.Xiaodong Yang · 1 companies · 1 sharedXiaodong YangApexigen, Inc. · $66.4M raisedApexigen, Inc.Francis SarenaFS
Francis Sarena Company Co-operator (ring = serial)Hover to isolate ties · click to open
Co-operators (shared boards)

People named alongside Francis Sarena on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.

OperatorSharedTheir companies
Scott Smith116
Gordon Ringold17
George Lee16
KAREN LIU14
Kenneth Fong13
William Rutter13
Amy Wong12
Dan Zabrowski12
Herb Cross11
Meenu Karson11
Frank Hsu11
Samuel Wertheimer11
William Duke, Jr.11
Ovid Trifan11
Xiaodong Yang11
Jakob Dupont11

People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.